KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity (2016 - 2020)

Nektar Therapeutics (NKTR) has 10 years of Debt to Equity data on record, last reported at $0.39 in Q1 2020.

  • For Q1 2020, Debt to Equity rose 159.22% year-over-year to $0.39; the TTM value through Mar 2020 reached $0.39, up 159.22%, while the annual FY2019 figure was $0.36, 148.88% up from the prior year.
  • Debt to Equity reached $0.39 in Q1 2020 per NKTR's latest filing, up from $0.36 in the prior quarter.
  • Across five years, Debt to Equity topped out at $72.16 in Q2 2017 and bottomed at -$880.47 in Q1 2016.
  • Average Debt to Equity over 5 years is -$46.96, with a median of $0.17 recorded in 2019.
  • Peak YoY movement for Debt to Equity: plummeted 54551.96% in 2016, then soared 1267.67% in 2017.
  • A 5-year view of Debt to Equity shows it stood at $2.76 in 2016, then increased by 1.06% to $2.79 in 2017, then tumbled by 94.85% to $0.14 in 2018, then skyrocketed by 148.88% to $0.36 in 2019, then increased by 9.71% to $0.39 in 2020.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.39 in Q1 2020, $0.36 in Q4 2019, and $0.17 in Q3 2019.